Vetmab Biosciences files Form D for equity offering worth nearly $12 million
The San Diego biotechnology company disclosed it has sold most of an equity offering under Regulation D, with about $505,000 left to sell.
Vetmab Biosciences, Inc. filed a Form D with the Securities and Exchange Commission disclosing a new notice of exempt securities offering. The filing lists the company as a Delaware corporation, incorporated in 2022, based in San Diego, California.1
According to the filing, the total offering amount is $11,944,990, of which $11,439,990 has already been sold, leaving $505,000 remaining to be sold.1 The offering was made under Rule 506(b) of Regulation D.1
The record states the date of first sale was September 17, 2026.1 The company indicated it does not intend the offering to last more than one year.1 The filing also shows a total of 30 investors have already invested in the offering.1
Vetmab lists no sales commissions or finder's fees, stating sales commissions of $0 and finders' fees of $0.1 The company also reported $0 in proceeds used for payments to executive officers, directors or promoters named in the filing.1
The filing identifies the company's industry as biotechnology within the health care sector.1 Related persons named in the filing include Denise Bevers and Richard Chin, both listed as executive officer and director,1 along with Hangjun Zhan, Neeraj Agrawal and Chrysa Mineo, each listed as directors.
The Form D was signed by Denise Bevers, Chief Executive Officer, on September 29, 2026.1 The filing does not specify how the remaining proceeds will be used or the purpose of the offering beyond the disclosed financial terms.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.